Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. [electronic resource]
Producer: 20120614Description: 1268-73 p. digitalISSN:- 1527-7755
- Adult
- Age Factors
- Aged
- Antineoplastic Agents, Hormonal -- administration & dosage
- Breast Neoplasms -- drug therapy
- Carcinoma in Situ -- drug therapy
- Carcinoma, Intraductal, Noninfiltrating -- drug therapy
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Kaplan-Meier Estimate
- Mastectomy, Segmental -- methods
- Middle Aged
- Neoplasm Invasiveness -- pathology
- Neoplasm Recurrence, Local -- mortality
- Neoplasm Staging
- Receptors, Estrogen -- analysis
- Receptors, Progesterone -- analysis
- Risk Assessment
- Survival Analysis
- Tamoxifen -- administration & dosage
- United States
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.